TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31116102

Group type: EXPERIMENTAL
Intervention: Behavioral therapy with diaphragmatic breathing and biofeedback therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baclofen at a dose of 10 mg three times daily
Number of subjects: 0
Study: 28179221

Group type: EXPERIMENTAL
Intervention: Daily sugar-sweetened beverage consumption
Number of subjects: 20
Study: 25589306

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (4 cycles of 1-min balloon occlusion separated by 1 min of deflation)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional primary PCI (control group)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 111
Study: 23458405

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300 mg/day for 40 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21819545

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) ∼1,000 kcal/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet, low-fat, reduced-carbohydrate, prescribed to decrease intake by ∼600 kcal/day
Number of subjects: 31
Study: 19160733

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17535863

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 15355146

Group type: EXPERIMENTAL
Intervention: Category tasks with a single relevant dimension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptually chaotic tasks requiring exemplar memorization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks based in XOR relations
Number of subjects: 0
Study: 11728627

Group type: COMPARATOR
Intervention: Subjects who withdrew consent
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Matched retained subjects
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Matched subjects who completed all required visits
Number of subjects: 70
Study: 10518851

Group type: EXPERIMENTAL
Intervention: Chlorine dioxide mouthrinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 12
Study: 7979805

Group type: EXPERIMENTAL
Intervention: Corrected seminal fructose measurement in leucocytospermics
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Serum testosterone measurement
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined measurement of serum testosterone and corrected seminal fructose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Seminal prolactin levels in leucocytospermic subjects
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Assessment of obstructive process
Number of subjects: 33
Study: 2661607

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 15
Study: 31098639

Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 12 weeks gestational age (wkGA)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 20 wkGA
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 28 wkGA
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 36 wkGA
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 24-28 wkGA
Number of subjects: 519

Group type: COMPARATOR
Intervention: PAPP-A at 12 wkGA
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placenta growth factor at 12 wkGA
Number of subjects: 519
Study: 30814417

Group type: EXPERIMENTAL
Intervention: Curcumin ingestion (180 mg/d) 4 d after exercise (POST)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Curcumin ingestion (180 mg/d) 7 d before exercise (PRE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (180 mg/d) 4 d after exercise (CON)
Number of subjects: 24
Study: 28857279

Group type: EXPERIMENTAL
Intervention: Sorbitol-containing chewing gum (with or without Magnolia bark extract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parafilm (control)
Number of subjects: 0
Study: 25288035

Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 821
Study: 23507997

Group type: EXPERIMENTAL
Intervention: Single bout of 60-min exercise (50% VO2 peak)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 38
Study: 21205939

Group type: EXPERIMENTAL
Intervention: Intraarterial administration of BM‐MNC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Repeated BM‐MNC administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Higher BM‐MNC numbers and functionality
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ulcer healing induced by repeated BM‐MNC administration
Number of subjects: 40
Study: 18434158

Group type: EXPERIMENTAL
Intervention: Off-the-shelf heel inserts
Number of subjects: 35

Group type: COMPARATOR
Intervention: No inserts
Number of subjects: 35
Study: 17119141

Group type: EXPERIMENTAL
Intervention: Standard open diskectomy
Number of subjects: 743

Group type: COMPARATOR
Intervention: Usual nonoperative care
Number of subjects: 743
Study: 15327525

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 256

Group type: COMPARATOR
Intervention: Low dose coumadin (1 mg/d)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH, enoxaparin 40 mg s.c. q.d.)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Thalidomide with full anticoagulation
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Thalidomide and chemotherapy during consolidation treatment
Number of subjects: 256
Study: 11416876

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9052314

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg cisatracurium
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg cisatracurium
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.15 mg/kg vecuronium
Number of subjects: 62
Study: 8134772

Group type: EXPERIMENTAL
Intervention: Five doses of ivermectin
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Single dose of ivermectin
Number of subjects: 893

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 893
Study: 3526522

Group type: EXPERIMENTAL
Intervention: TL-102 (beclomethasone dipropionate powder preparation) 50 micrograms with 30 micrograms of hydroxypropylcellulose, administered intranasally at a dose of 2 capsules/day b.i.d. for one week
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: TL-102 (beclomethasone dipropionate powder preparation)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional BDP preparations
Number of subjects: 250
Study: 29771450

Group type: EXPERIMENTAL
Intervention: AHM trial
Number of subjects: 23

Group type: COMPARATOR
Intervention: PLAC trial
Number of subjects: 23

Group type: COMPARATOR
Intervention: PLAC+EXER trial
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: AHM+EXER trial
Number of subjects: 23
Study: 27055601

Group type: EXPERIMENTAL
Intervention: Relamorelin 10 μg twice daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 25027701

Group type: EXPERIMENTAL
Intervention: Thiamin supplementation (10 mg/day for 7 days, then 5 mg daily until day 42)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo (identical oral placebo)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Thiamin supplementation
Number of subjects: 630

Group type: COMPARATOR
Intervention: Thiamin supplementation and Placebo
Number of subjects: 630
Study: 22695018

Group type: EXPERIMENTAL
Intervention: 1 microplate (subapical) and 1 miniplate (at the lower border)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2-miniplate protocol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (1 microplate + 1 miniplate and 2-miniplate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 20187947

Group type: EXPERIMENTAL
Intervention: Early medication change (EMC) strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 18176739

Group type: EXPERIMENTAL
Intervention: Women with spinal cord injury
Number of subjects: 545

Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 545
Study: 16307968

Group type: COMPARATOR
Intervention: GnRH agonist (Leuprorelin 3.75 mg/28 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subdermal progestin implant (etonogestrel 68 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 12660529

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both Nelfinavir and Efavirenz
Number of subjects: 131
Study: 10714913

Group type: COMPARATOR
Intervention: Calcium alone (750 mg)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 microg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 microg
Number of subjects: 146
Study: 9175942

Group type: EXPERIMENTAL
Intervention: Score developed based on multiple regression analysis including birthweight, Apgar score at 5 minutes, base excess at admission, severity of respiratory distress syndrome, and artificial ventilation.
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Score validation cohort (cutoff of 21).
Number of subjects: 572

Group type: COMPARATOR
Intervention: Comparison of risk adjusted mortality between two eras (1978-87 and 1988-91).
Number of subjects: 572
Study: 1539788

Group type: EXPERIMENTAL
Intervention: Posterior approach sciatic nerve block (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Popliteal fossa approach sciatic nerve block (group B)
Number of subjects: 40
Study: 2951808

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (200, 1,000, and 2,000 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28953076

Group type: EXPERIMENTAL
Intervention: Vesair Balloon placement
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (sham-controlled)
Number of subjects: 221
Study: 26405233

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow-derived cells (BMC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25350669

Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 IU once a week for 2 months and then monthly for 10 months
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 22406101

Group type: EXPERIMENTAL
Intervention: Behavior Activation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Supportive Therapy (Control)
Number of subjects: 200
Study: 20513174

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglyceride (MCT) oil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dissolving thin film strips
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gelatin capsules
Number of subjects: 90
Study: 18794541

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT arm; fluorouracil [FU] 400 mg/m(2) IV once daily plus dl‐leucovorin 200 mg/m(2) for 5 days or FU 370 mg/m(2) plus l‐leucovorin 100 mg/m(2) IV for 5 days for six cycles at 28-day intervals)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT arm)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Surgery alone (S arm)
Number of subjects: 278
Study: 16101723

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 115

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 115
Study: 12434284

Group type: EXPERIMENTAL
Intervention: Consumption of fruits and vegetables (highest vs lowest quintile)
Number of subjects: 27111

Group type: EXPERIMENTAL
Intervention: Consumption of specific groups of fruits and vegetables (berries and cruciferous vegetables)
Number of subjects: 27111

Group type: EXPERIMENTAL
Intervention: Dietary intakes of alpha-carotene, beta-carotene, lycopene, lutein/zeaxanthin, beta-cryptoxanthin, vitamins A, E, and C, and folate
Number of subjects: 27111
Study: 9683312

Group type: EXPERIMENTAL
Intervention: Controlled onset-extended release (COER)-verapamil (180 mg/d)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Standard of care (SOC) including hydrochlorothiazide (HCTZ) or atenolol
Number of subjects: 15000
Study: 7655108

Group type: EXPERIMENTAL
Intervention: Calcipotriol in ointment for 12 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ointment base only for 12 weeks
Number of subjects: 2
Study: 2832568

Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Number of subjects: 13

Group type: COMPARATOR
Intervention: Liquid control meals
Number of subjects: 13
Study: 30341006

Group type: COMPARATOR
Intervention: Cligosiban 0.3-2,400 mg (aqueous solutions or dispersions)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cligosiban 800 mg (capsules and aqueous dispersion)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cligosiban 1,600 mg (caplets and aqueous dispersion)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cligosiban (various doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cligosiban (800 mg)
Number of subjects: 34
Study: 28375108

Group type: EXPERIMENTAL
Intervention: Gingocap
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pyridoxine
Number of subjects: 65
Study: 24714097

Group type: EXPERIMENTAL
Intervention: PIPJ-based emollients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petrolatum-based emollients
Number of subjects: 0
Study: 23638997

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 32
Study: 21780209

Group type: EXPERIMENTAL
Intervention: Flavanol-rich lychee fruit extract (FRLFE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19455053

Group type: EXPERIMENTAL
Intervention: High-dose CP-532,623
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose CP-532,623
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP-532,623
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Torcetrapib and CP-532,623
Number of subjects: 0
Study: 16434254

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15272911

Group type: EXPERIMENTAL
Intervention: TT subjects during sodium restriction
Number of subjects: 44

Group type: COMPARATOR
Intervention: C allele subjects
Number of subjects: 44
Study: 11379808

Group type: EXPERIMENTAL
Intervention: HFA-BDP (200 to 800 microg daily)
Number of subjects: 473

Group type: COMPARATOR
Intervention: CFC-BDP (400 to 1600 microg daily)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: HFA-BDP
Number of subjects: 473

Group type: COMPARATOR
Intervention: CFC-BDP
Number of subjects: 473
Study: 9216523

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 12

Group type: COMPARATOR
Intervention: White soft paraffin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitric oxide production
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Number of subjects: 12
Study: 8481621

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg and 400 mg)
Number of subjects: 10
Study: 4018941

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive diuresis
Number of subjects: 0
Study: 30964889

Group type: EXPERIMENTAL
Intervention: RNA-seq analysis of male and female progeny plants
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RNA-seq analysis of 39 sex-chromosomal genes
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Analysis using a large-scale population (>1400) and over 100 spinach germplasm accessions and cultivars
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Synonymous substitution rates of the MSY genes and X homologues
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Comparative analysis with S. tetrandra
Number of subjects: 140
Study: 29195133

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-DHA fish oil (high-DHA-FO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 34
Study: 27051055

Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin (50 mg/m2) for 60 minutes after complete cytoreduction.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard first-line treatment (6 conventional cycles of chemotherapy after CS with HIPEC).
Number of subjects: 19
Study: 24571858

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (median 3 units, interquartile range 2-5)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 213
Study: 22614720

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with 67 mg caffeine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with 134 mg caffeine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regular coffee (130 mg caffeine)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo-control capsule
Number of subjects: 21
Study: 20135748

Group type: EXPERIMENTAL
Intervention: Probiotics (Bio-three: Bacillus mesentericus, Enterococcus faecalis, Clostridium butyricum)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Probiotics (Bio-three)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 19226018

Group type: EXPERIMENTAL
Intervention: Morcellized bone grafting
Number of subjects: 29
Study: 17845947

Group type: EXPERIMENTAL
Intervention: Surveys distributed at work
Number of subjects: 1954

Group type: COMPARATOR
Intervention: Surveys mailed directly to homes
Number of subjects: 1954
Study: 15025848

Group type: EXPERIMENTAL
Intervention: Liquid formulation of r-hCG (0.5 mL of 250 microg/0.5 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Freeze-dried formulation of r-hCG (1.0 mL of 250 microg/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study: 10990077

Group type: EXPERIMENTAL
Intervention: Oral insulin (5 mg daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 9365349

Group type: EXPERIMENTAL
Intervention: Active magnetic device (300 to 500 Gauss)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 50
Study: 1315383

Group type: EXPERIMENTAL
Intervention: Org 2766
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3966831

Group type: EXPERIMENTAL
Intervention: Moxalactam (MOX)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Tobramycin and Clindamycin (TM/C)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Vitamin K treatment
Number of subjects: 94
Study: 31065731

Group type: EXPERIMENTAL
Intervention: MDMA (75–125 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo/control (0–40 mg)
Number of subjects: 103
Study: 27783849

Group type: EXPERIMENTAL
Intervention: Peptide cocktail therapy (KIF20A-derived peptide vaccine combined with antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2) plus gemcitabine
Number of subjects: 68
Study: 25732978

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS‐Medtronic) calibrated by the glucometer Calla, Wellion, Austria
Number of subjects: 12
Study: 23540891

Group type: EXPERIMENTAL
Intervention: SB203580
Number of subjects: 23

Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 23

Group type: COMPARATOR
Intervention: SAH
Number of subjects: 23
Study: 21536936

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 19239406

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coagulation factors VIII (FVIII)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coagulation factors XIII (FXIII)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 40 vol% gelatin dilution
Number of subjects: 12
Study: 16175627

Group type: EXPERIMENTAL
Intervention: modafinil
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 12899793

Group type: EXPERIMENTAL
Intervention: rhIFN-gamma (1 MU intramuscularly daily for the first three months and 1 MU every other day for the following six months)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: rhIFN-gamma
Number of subjects: 289
Study: 10709154

Group type: EXPERIMENTAL
Intervention: 2.5 mg risedronate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 30 mg risedronate
Number of subjects: 23
Study: 9199591

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo mouthrinse)
Number of subjects: 30
Study: 1491149

Group type: EXPERIMENTAL
Intervention: Infrared emission detection tympanic thermometers with ear tug technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infrared emission detection tympanic thermometers without ear tug technique
Number of subjects: 40
Study: 3903647

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 30953319

Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg once daily for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLPG1690 (various doses from 20 mg to 1500 mg, including multiple daily doses of 300-1000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GLPG1690 600 mg
Number of subjects: 0
Study: 29990653

Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 364

Group type: COMPARATOR
Intervention: Project Health
Number of subjects: 364